The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1527
Cardiovascular Effects of Some Antidiabetic Drugs
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 8/25/17: See GLP-1 Receptor Agonists, end of first paragraph.

For many years, the goal of drug therapy for most patients with type 2 diabetes has been to achieve and maintain an A1C of <7%. Achieving that goal can prevent microvascular complications (diabetic retinopathy, nephropathy, neuropathy), but whether it prevents macrovascular complications (myocardial infarction [MI], stroke) has been less clear. The FDA now requires that cardiovascular safety studies be performed for all new drugs for type 2 diabetes.1 Recent findings that some of the newer second-line drugs for type 2 diabetes have cardiovascular benefits have led to new interest in the cardiovascular efficacy and safety of all antidiabetic drugs.2,3

METFORMIN — The oral biguanide metformin (Glucophage, and others) is the drug of choice for initial treatment of type 2 diabetes, but its cardiovascular effects have not been ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Cardiovascular Effects of Some Antidiabetic Drugs
Article code: 1527c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian